Today I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.
This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped – making this is yet another stock that sells off after a slight miss, a dispiriting trend.
But that's okay. Wall Street's ignorance gives us an entry point the likes of which we probably won't see again for years.
I'm going to show you how Wall Street got it wrong – and why today's recommendation is actually a huge profit opportunity. And we're going to pick this biotech stock up using a strategy perfect for current market conditions.
Let's take a look…
Missing the Signals
According to this company's third-quarter earnings report, the biotech's blockbuster drug, one of the most successful pharmaceuticals ever, is quickly losing steam less than a year after its debut.
That may be true, but here's what Wall Street missed.
Those sales are slowing down for a simple but lucrative reason. The company is set to release a new drug that will soon replace this blockbuster – and that may do even better.
On Oct. 28, Gilead Sciences Inc. (Nasdaq: GILD) said sales of its hepatitis C treatment Sovaldi fell by 20% from the second to third quarter. Analysts called for sales of $2.93 billion but they came in 4.4% short at $2.8 billion.
The company reported adjusted earnings per share of $1.84. That missed the Street's consensus estimate of $1.92 by almost the same amount as the shortfall in Sovaldi sales.
And the arrival of Gilead's new drug is not the only signal Wall Street missed.
First, Gilead had blowout earnings for the period – they soared a stunning 254%.
Second, Sovaldi is almost certainly going to go down in history as one of the more successful drugs ever launched. In roughly 10 months, it racked up sales of nearly $8.7 billion treating 117,000 patients.
Just One "Hiccup" for This Biotech Stock
And then there's that new hepatitis C treatment.
Less than three weeks before the earnings announcement, Gilead received U.S. Food and Drug Administration approval for Harvoni. This compound combines Sovaldi with other ingredients. And that means patients will need to take only that one drug over a course of 12 weeks of therapy.
A round of treatment with Harvoni costs $94,500, but it is much more convenient and may also prove to be more effective than Sovaldi.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.